Equillium, Inc. Overview
EQ market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 1.33
- H
- 1.37
- L
- 1.27
- C
- 1.33
- Vol
- 8,772.00
Daily history from Oct 12, 2018
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $1.33
- Previous Close
- $1.39
- Day High
- $1.37
- Day Low
- $1.27
- 52 Week High
- $3.47
- 52 Week Low
- $0.79
- 7 Day Return
- -6.99%
- 30 Day Return
- -6.99%
- 90 Day Return
- -36.97%
- 1 Year Return
- +4.72%
- Daily Notional Volume
- $11.7K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.39 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -19.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.76 – $3.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $89.4M · P/B 3.30 · P/S 2.18.